MeSH D065766 - atypical hemolytic uremic syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals | Eculizumab | Soliris | 2007-03-16 | $4,068.9 M | Q2/20-Q1/21 | |
| Ravulizumab | Ultomiris | 2018-12-21 | $1,200.8 M | Q2/20-Q1/21 | ||
| Amgen | Eculizumab | Bekemv | 2023-04-19 |
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
33%1/3
Phase 3
63%5/8
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use